Navigation Links
Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology
Date:10/25/2011

ng or breathing difficulties may be more susceptible to these complications. In most cases, this is a consequence of weakening of muscles in the area of injection that are involved in breathing or swallowing. When distant effects occur, additional respiratory muscles may be involved [See Boxed Warning]. Deaths as a complication of severe dysphagia have been reported after treatment with botulinum toxin. Dysphagia may persist for several months, and require use of a feeding tube to maintain adequate nutrition and hydration. Aspiration may result from severe dysphagia and is a particular risk when treating patients in whom swallowing or respiratory function is already compromised. These reactions can occur within hours to weeks after injection with botulinum toxin.
  • Cervical Dystonia: Patients with smaller neck muscle mass and patients who require bilateral injections into the sternocleidomastoid muscles are at greater risk of dysphagia. Limiting the dose injected into the sternocleidomastoid muscle may decrease the occurrence of dysphagia.

  • Blepharospasm: Injection of XEOMIN into the orbicularis oculi muscle may lead to reduced blinking and corneal exposure with possible ulceration or perforation. Lower lid injections should not be repeated if diplopia occurred with previous botulinum toxin injections.

  • Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junctional disorders (e.g., myasthenia gravis or Lambert-Eaton syndrome) should be monitored particularly closely when given botulinum toxin. Patients with neuromuscular disorders may be at increased risk of clinically significant effects including severe dysphagia and respiratory compromise from typical doses of XEOMIN.

  • ADVERSE REACTIONSCervical Dystonia: The most commonly observed adverse reactions (incidence greater than or equal to 10% of patients and twice the rate of placebo) for XEOMIN 120 Units
    '/>"/>

    SOURCE Merz Pharmaceuticals
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. FDA Approves Merz Pharmaceuticals Xeomin® (incobotulinumtoxinA) for the Treatment of Cervical Dystonia and Blepharospasm
    2. Xeomin® (incobotulinumtoxinA) - a Botulinum Toxin Free From Accessory Proteins - Now Available in the U.S.
    3. Xeomin® (incobotulinumtoxinA) Data To Be Presented At The 71st Annual Assembly Of The American Academy Of Physical Medicine And Rehabilitation
    4. Merz Pharmaceuticals Introduces Comprehensive Programs to Provide Patients With Financial Assistance for Xeomin® (incobotulinumtoxinA)
    5. Merz Pharmaceuticals Announces New Centers for Medicare and Medicaid Billing Q-Code for Xeomin® (incobotulinumtoxinA)
    6. New Data On Xeomin® (IncobotulinumtoxinA) To Be Presented At The 15th International Congress Of Parkinsons Disease And Movement Disorders (MDS)
    7. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
    8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
    9. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
    10. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
    11. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... plc (LSE: SHP, NASDAQ: SHPG ) announces that it ... the announced tender offer for all of the outstanding shares of ... the waiver, the transaction is no longer conditional on OFT approval, ... 2014 following the currently scheduled expiration time, subject to the satisfaction ...
    (Date:1/15/2014)...  Manufacturers, suppliers and distributors of innovative medical-related products ... most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the Medical ... most litigious industry sectors of cases involving IP ...
    (Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: ... concerning composition of matter, biological targets, mechanism of action, ... This patent application describes a novel ... (VSRNAs) which interfere with the basic homeostatic cellular processes ...
    Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
    ... Medical - SECRITT I Study to Evaluate Preventive Treatment ... Potentially Life Threatening Vulnerable Plaques, ... cardiology team led by Professor Patrick W. Serruys,successfully placed ... coronary artery of a 64-year-old man at Erasmus Medical,Center ...
    ... -- 10:00 a.m. EDT, 7:00 a.m. PDT ... -- 877-548-7901 ... http://www.isispharm.com , SAN DIEGO, June 30 Isis Pharmaceuticals,(Nasdaq: ISIS ) will conduct a ... TV-1102 clinical trial,and the ATL / TEVA / Isis relationship., -- ATL and TEVA announced clinical ...
    Cached Medicine Technology:Patient Receives vProtect(TM) Luminal Shield in First-Ever Vulnerable Plaque Clinical Trial 2Patient Receives vProtect(TM) Luminal Shield in First-Ever Vulnerable Plaque Clinical Trial 3Isis Pharmaceuticals Conference Call Notice 2
    (Date:4/17/2014)... 2014) Population Council scientists and their partners have found ... can prevent the transmission of multiple sexually transmitted infections ... HIV, herpes simplex virus 2 (HSV-2), and human papillomavirus ... that the gel is effective against multiple strains of ... vagina against all three viruses of at least eight ...
    (Date:4/17/2014)... The world is less than 40 years away from ... people and governments, according to a top scientist at ... time in human history, food production will be limited ... water and energy," said Dr. Fred Davies, senior science ... issues could become as politically destabilizing by 2050 as ...
    (Date:4/17/2014)... Belfast,s Vice-Chancellor, Professor Patrick Johnston, whose work has transformed ... a Fellow of the European Academy of Cancer Sciences., ... independent advisory body of highly distinguished oncologists and cancer ... caused by cancer in Europe. , Professor Johnston, whose ... move from the bottom of the UK league table ...
    (Date:4/16/2014)... April 15, 2014 The Translational Genomics Research Institute ... annual Founders Dinner for their support of TGen,s research ... place March 28 in Scottsdale. , Catherine Ivy, Founder ... received TGen,s John S. McCain Leadership Award, named for ...
    (Date:4/16/2014)... that fertility treatments are the leading cause of increases ... risk of premature birth, these results are not inevitable, ... . The article identifies six changes in policy ... births and prematurity, including expanding insurance coverage for in ...
    Breaking Medicine News(10 mins):Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2Health News:Food shortages could be most critical world issue by mid-century 2Health News:TGen honors Catherine Ivy and Craig Jackson with Leadership; Collaborative Spirit awards 2Health News:Preterm births, multiples, and fertility treatment 2Health News:Preterm births, multiples, and fertility treatment 3
    ... Inc. (Nasdaq: SMBL ) announced today Steven Hughes, ... make a presentation at the Roth Capital Partners 21st Annual ... EST on Tuesday, February 17, 2009.Smart Balance,s presentation will be ... be able to ask questions, but listeners to the webcast ...
    ... from the clinical research community have already pledged ... American National Standards Institute (ANSI), coordinator ... is working to facilitate the use of electronic ... The Institute seeks the active engagement and financial ...
    ... Feb. 13 Dynatronics Corporation (Nasdaq: DYNT ) ... months ended December 31, 2008. Operating results showed significant improvement ... Pre-tax profit for the quarter ended December 31, 2008, improved ... the second quarter of the prior fiscal year. Net income ...
    ... BETHESDA, Md., Feb. 13 Micromet, Inc. (Nasdaq: MITI ), ... the ROTH 21st Annual Orange County Growth Stock Conference at the Ritz-Carlton ... The ROTH 21st Annual Orange County Growth Stock Conference, ... 4:30 pm Pacific Time, Place: The Ritz-Carlton ...
    ... SAN FRANCISCO, Feb. 13, 2009 New techniques used ... in the wild are yielding surprising results about hormones ... the social structure of a broader range of mammals. ... present findings at the AAAS meeting that examine social ...
    ... Applauds Senator Rockefeller and Representative Filner for Introducing ... Federation of Government Employees (AFGE) today applauded the ... the Senate Committee on Veterans, Affairs and Representative ... Veterans, Affairs for authoring legislation to amend Section ...
    Cached Medicine News:Health News:ANSI Seeks Funding to Ensure that Electronic Health Records Will Support Clinical Research Activities 2Health News:ANSI Seeks Funding to Ensure that Electronic Health Records Will Support Clinical Research Activities 3Health News:ANSI Seeks Funding to Ensure that Electronic Health Records Will Support Clinical Research Activities 4Health News:Dynatronics Reports Profitable Second Quarter - Signaling Significant Improvement Over Prior Year Results 2Health News:Dynatronics Reports Profitable Second Quarter - Signaling Significant Improvement Over Prior Year Results 3Health News:Dynatronics Reports Profitable Second Quarter - Signaling Significant Improvement Over Prior Year Results 4Health News:Micromet To Present at the ROTH 21st Annual Orange County Growth Stock Conference 2Health News:Micromet To Present at the ROTH 21st Annual Orange County Growth Stock Conference 3Health News:Micromet To Present at the ROTH 21st Annual Orange County Growth Stock Conference 4Health News:Findings raise new questions about evolution of hormones in mammals 2Health News:Veterans' Affairs Employee Union Urges Congress to Strengthen Collective Bargaining Rights at VA Hospitals 2
    ... ML1 Manual Lensometer combines the traditional ... advantages, such as LED illumination and ... light source provides a clear green ... operated and completely cordless, the ML1 ...
    ... The Ultramatic RX Master Phoroptor ... - continues to be the industry standard ... that unmistakable feel of quality. The smooth ... of play in the mechanisms. The precise, ...
    The Maverick Over-The-Wire balloon catheter delivers a new level of performance to meet the changing demands of interventional cardiology....
    ... The Illuminated Phoroptor features lighted dials ... to perform refractions in the darkened setting ... pen light and leave the lights off ... features lighted sphere, cylinder power and cylinder ...
    Medicine Products: